Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (291-300 of 347) with videos related to

Pageof 35
Sort By:
Thoracic Cancer|July 17, 2021
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trialJianhua Shi, Guimin Chen, Haitao Wang, et al.
Signal Transduction and Targeted Therapy|April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 studyLin Gui, Haifeng Liu, Huaqing Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
JAMA Oncology|August 12, 2018
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical TrialBaohui Han, Kai Li, Qiming Wang, et al.
American Journal of Hematology|January 21, 2018
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label studyCarlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Cancer Research|April 18, 2013
DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancerJianzhong Cao, Yongmei Song, Nan Bi, et al.
Cancer Communications (London, England)|May 26, 2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialYuankai Shi, Jin Li, Jianming Xu, et al.
The Lancet. Haematology|January 8, 2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Hang Su, Yongping Song, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancerXiaoyan Si, Li Zhang, Hanping Wang, et al.
Pageof 35

Showing results (291-300 of 347) with videos related to

Sort By:
Pageof 35
Thoracic Cancer|July 17, 2021
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trialJianhua Shi, Guimin Chen, Haitao Wang, et al.
Signal Transduction and Targeted Therapy|April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 studyLin Gui, Haifeng Liu, Huaqing Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
JAMA Oncology|August 12, 2018
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical TrialBaohui Han, Kai Li, Qiming Wang, et al.
American Journal of Hematology|January 21, 2018
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label studyCarlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Cancer Research|April 18, 2013
DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancerJianzhong Cao, Yongmei Song, Nan Bi, et al.
Cancer Communications (London, England)|May 26, 2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialYuankai Shi, Jin Li, Jianming Xu, et al.
The Lancet. Haematology|January 8, 2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Hang Su, Yongping Song, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancerXiaoyan Si, Li Zhang, Hanping Wang, et al.
Pageof 35